FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant _____ Jonaki Bose_____________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

__________________________
Signature______ Jonaki Bose

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Boyer

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

none

Signature:

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant John T. Brooks

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

None

Signature

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant _____Daniel Budnitz______________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

Signature ____________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

**Note to Speakers:** We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant __Theresa Cassidy_________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

Theresa Cassidy is an employee of Inflexxion, Inc. Inflexxion has contracts to conduct post-market surveillance and studies of prescription medication abuse with various pharmaceutical companies.

Signature____________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant  **Daniel Ciccarone  MD, MPH**

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No Conflicts

________________________________________

Signature

___________________________

Please email the form to Cherice Holloway ([Cherice.Holloway@fda.hhs.gov](mailto:Cherice.Holloway@fda.hhs.gov)) by June 23, 2017.

**Note to Speakers:** We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ______ Wilson M. Compton ______________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

Dr. Compton reports long term, minimal stock holdings in Pfizer Inc., General Electric Co., and 3M Companies unrelated to the meeting topic.

__________________________________________________________

__________________________________________________________

__________________________________________________________

Signature ______________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

**Note to Speakers:** We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant __Frederick Conrad_________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

NONE

Signature __Frederick Conrad_____________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant  Elizabeth H. Crane

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts.

__________________________________________________________

Signature  [Signature]

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Nabarun Dasgupta, MPH, PhD

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

ND is a part-time employee of the RADARS System.

________________________________________________________

________________________________________________________

Signature

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant **Carol DeFrances**

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

*No conflicts*

________________________________________

________________________________________

________________________________________

________________________________________

Signature **Carol DeFrances**

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

**Note to Speakers:** We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Louisa Degenhardt

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

I have received investigator-initiated untied educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine-naloxone, buprenorphine depot, naloxone, the development of an opioid-related behaviour scale, and a study of opioid substitution therapy uptake among chronic non-cancer pain patients. I have received investigator-initiated untied educational grants for the conduct of post-marketing surveillance of a potentially tamper-resistant formulation of controlled-release oxycodeone from Mundipharma.

Signature

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant_Barry I Graubard___________________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

Own stock in Medtronic

___________________________

Signature

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting  
Data and Methods for Evaluating the Impact of Opioid Formulations  
With Properties Designed to Deter Abuse in the Postmarket Setting  

July 10-11, 2017  
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant  Jody L. Green

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

I have no personal conflicts of interest. All research and consulting funding is awarded to my employer, the Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. DHHA independently owns and operates the RADARS System which is supported by subscriptions from pharmaceutical manufacturers for surveillance, research and reporting services.

Signature  

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Holly Hedegaard, MD, MSPH

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts.

__________________________________________________________

Signature: ____________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

**Note to Speakers:** We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Christopher M. Jones

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

no conflicts

Signature: [signature]

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Erin E. Krebs

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts.

_____________________________________
Signature

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Peter W. Kreiner

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts," sign and return the form.

No conflicts.

____________________________________________________________________

Signature: [Signature]

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant __Vincent Lo Re_______________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

AstraZeneca: saxagliptin
International Society for Pharmacoepidemiology, Board of Directors

__________________________________________________________

Signature ________________ 6/26/2017

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant _F Leland McClure, MSci, PhD, F-ABFT_________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

Employed by Quest Diagnostics
Consult for SAMHSA Workplace Drug Testing, Research Triangle Institute, RTP, NC

Signature ____________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations With Properties Designed to Deter Abuse in the Postmarket Setting
July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant: Richard Miech

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

______________________________

Signature

Richard Miech

Please email the form to Cherice Holloway ([Cherice.Holloway@fda.hhs.gov](mailto:Cherice.Holloway@fda.hhs.gov)) by June 23, 2017.

**Note to Speakers:** We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant __Scott P. Novak__________________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

Endo Pharmaceuticals, Indivior, PLC, Pfizer, Shire, Purdue, Zogenix,

____________________________________________________________________

____________________________________________________________________

____________________________________________________________________

Signature __________________________________________________________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant  Jennifer Parker

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

Signature

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant __Dr. Elizabeth J. Scharman______________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

________________________________________________________________________

No conflicts.

________________________________________________________________________

________________________________________________________________________

Signature ________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

**Note to Speakers:** We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant ___Sidney H. Schnoll, MD, PhD_____________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

I am an employee of Pinney Associates, Inc., which consults with numerous pharmaceutical companies on the development and post-marketing surveillance of abuse deterrent opioid products.

__________________________________________
__________________________________________
__________________________________________

Signature________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant _Abigail Shoben____________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

______________________________________________________________

Signature ____________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: George Jay Unick

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No Conflicts

__________________________________________

Signature

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.
Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant __Almut Winterstein________________________

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

________________________________________

Signature________________________________

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.